Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial

The Lancet Neurology

Fecha de publicación: 26 de febrero de 2021

DOI: https://doi.org/10.1016/S1474-4422(20)30483-X

Autores: Prof Mikael Mazighi, MD , Prof Sebastien Richard, MD, Bertrand Lapergue, MD, Prof Igor Sibon, MD, Prof Benjamin Gory, MD, Jerome Berge, MD, Arturo Consoli, MD, Julien Labreuche, BST, Prof Jean-Marc Olivot, MD, Prof Joseph Broderick, MD, Prof Alain Duhamel, PhD, Prof Emmanuel Touze, MD, Prof Adnan I Qureshi, MD, Amélie Yavchitz, MD Simon Escalard, MD, Jean-Philippe Desilles, MD, Hocine Redjem, MD, Stanislas Smajda, MD, Robert Fahed, MD, Solène Hébert, MD, Benjamin Maïer, MD, François Delvoye, MD, Perrine Boursin, RN, Malek Ben Maacha, MSc, Michael Obadia, MD, Candice Sabben, MD, Raphael Blanc, MD, Julien Savatovsky, MD, Michel Piotin, MD

Background: High systolic blood pressure after successful endovascular therapy for acute ischaemic stroke is associated with increased risk of intraparenchymal haemorrhage. However, no randomised controlled trials are available to guide optimal management. We therefore aimed to assess whether an intensive systolic blood pressure target resulted in reduced rates of intraparenchymal haemorrhage compared with a standard systolic blood pressure target.